Activation of RAF-1 through Ras and Protein Kinase Calpha Mediates 1alpha ,25(OH)2-Vitamin D3 Regulation of the Mitogen-activated Protein Kinase Pathway in Muscle Cells*

Claudia Graciela Buitrago, Verónica González Pardo, Ana R. de Boland, and Ricardo BolandDagger

From the Departamento de Biología, Bioquímica and Farmacia, Universidad Nacional del Sur, San Juan 670, 8000 Bahía Blanca, Argentina

Received for publication, June 10, 2002, and in revised form, October 7, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

We have previously shown that stimulation of proliferation of avian embryonic muscle cells (myoblasts) by 1alpha ,25(OH)2-vitamin D3 (1alpha ,25(OH)2D3) is mediated by activation of the mitogen-activated protein kinase (MAPK; ERK1/2). To understand how 1alpha ,25(OH)2D3 up-regulates the MAPK cascade, we have investigated whether the hormone acts upstream through stimulation of Raf-1 and the signaling mechanism by which this effect might take place. Treatment of chick myoblasts with 1alpha ,25(OH)2D3 (1 nM) caused a fast increase of Raf-1 serine phosphorylation (1- and 3-fold over basal at 1 and 2 min, respectively), indicating activation of Raf-1 by the hormone. These effects were abolished by preincubation of cells with a specific Ras inhibitor peptide that involves Ras in 1alpha ,25(OH)2D3 stimulation of Raf-1. 1alpha ,25(OH)2D3 rapidly induced tyrosine de-phosphorylation of Ras-GTPase-activating protein, suggesting that inhibition of Ras-GTP hydrolysis is part of the mechanism by which 1alpha ,25(OH)2D3 activates Ras in myoblasts. The protein kinase C (PKC) inhibitors calphostin C, bisindolylmaleimide I, and Ro 318220 blocked 1alpha ,25(OH)2D3-induced Raf-1 serine phosphorylation, revealing that hormone stimulation of Raf-1 also involves PKC. In addition, transfection of muscle cells with an antisense oligodeoxynucleotide against PKCalpha mRNA suppressed serine phosphorylation by 1alpha ,25(OH)2D3. The increase in MAPK activity and tyrosine phosphorylation caused by 1alpha ,25(OH)2D3 could be abolished by Ras inhibitor peptide, compound PD 98059, which prevents the activation of MEK by Raf-1, or incubation of cell lysates before 1alpha ,25(OH)2D3 exposure with an anti-Raf-1 antibody. In conclusion, these results demonstrate for the first time in a 1alpha ,25(OH)2D3 target cell that activation of Raf-1 via Ras and PKCalpha -dependent serine phosphorylation plays a central role in hormone stimulation of the MAPK-signaling pathway leading to muscle cell proliferation.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

Raf-1 was discovered as the first member of a cytoplasmatic family of serine/threonine kinases and plays a crucial role in the activation of the classical cytoplasmatic-signaling cascade that is involved in the regulation of cellular proliferation, differentiation, and apoptosis (1). Activation of Raf-1 downstream of protein-tyrosine kinase receptors is mediated by the Ras GTP-binding proteins, which are required for stimulation of Raf-1 kinase activity (2, 3). Raf-1 then phosphorylates and activates the mitogen-activated protein kinase kinase, also known as MEK1 (4), initiating a protein kinase cascade that follows with the phosphorylation and activation of the extracellular signal-regulated mitogen-activated protein (MAP) kinase isoforms ERK1 and ERK2 (5). Upon activation, MAP kinase (MAPK) is translocated from the cytoplasm into the nucleus (6), where it phosphorylates transcription factors (7) and culminates in proliferation or differentiation of a variety of cell types.

With an estimated molecular mass of 74 kDa, Raf-1 possesses three conserved regions, CR1, CR2, and CR3, that are embedded in variable regions. The CR1 and CR2 domains are part of the regulatory N-terminal half of the Raf-1 protein, whereas CR3 forms the C-terminal kinase domain (1). The molecular mechanism of Raf-1 activation, however, is still unclear. Although Raf-1 binds directly to the effector domain of activated GTP-bound Ras proteins, this interaction does not appear to stimulate Raf-1 kinase activity (8). Rather, it seems that the role of the Ras-Raf interaction is to recruit Raf-1 to the plasma membrane, where it can be activated by membrane lipids or other protein kinases, the nature of which remains to be determined (9, 10). Phosphorylation of Raf on both tyrosine and serine/threonine residues is required for enzymatic activity (11). It has been shown that the Src protein-tyrosine kinase can activate Raf by phosphorylation on Tyr-340 and Tyr-341 (12, 13). However, mutant Raf proteins in which Tyr-340 and Tyr-341 have been changed to Asp can still be activated after membrane association, indicating that an additional mechanism(s) of Raf activation exists (13). Among the mechanisms involved, there is evidence for the operation of both protein kinase C (PKC)-dependent and PKC-independent pathways of Raf activation in response to agonists (14).

The 13 members of the PKC family can be grouped into three major classes of Ca2+-dependent classical PKCs, Ca2+-independent, novel PKCs, and Ca2+- and lipid-independent, atypical PKCs. There is a fourth PKC subgroup consisting of PKCµ (15). Previous reports showed that classical and novel PKCs activate the MAP kinase pathway at the level of Raf-1, whereas atypical PKCs activate MEK by an independent mechanism (16, 17). One of the classical PKCs, PKCalpha can directly activate Raf-1 by serine phosphorylation of Raf-1 (18).

The steroid hormone 1alpha ,25-dihydroxy-vitamin D3 (1alpha ,25(OH)2D3) triggers responses in muscle cells both through a nuclear receptor-mediated mechanism that promotes gene transcription (19) and a fast non-genomic mode of action independent of new RNA and protein synthesis (20, 21). In previous work we have demonstrated that the steroid hormone rapidly stimulates in skeletal muscle cells the phosphorylation and activity of the MAP kinase isoforms ERK1 and ERK2 and have implicated the MAPK cascade in hormone control of myoblast proliferation (22). Moreover, initial investigations on the mechanisms underlying 1alpha ,25(OH)2D3 stimulation of the muscle cell (myoblast) MAPK pathway revealed that PKC and Ca2+ are two upstream activators mediating the hormone effect (23). In addition, it has been shown that 1alpha ,25(OH)2D3 enhancement of myoblast proliferation correlates to increased PKCalpha expression, whereas decreased PKCalpha levels are observed during the subsequent activation of muscle cell differentiation by the hormone (24). Furthermore, inhibition of PKCalpha expression by using antisense oligonucleotide technology resulted in a significant decrease of culture cell density and DNA synthesis, clearly showing that this isozyme is involved in signaling cascades that promote muscle cell proliferation (25).

The upstream-signaling pathway that leads to activation of the Ras/Raf-1/MAPK (ERK1/2) cascade by 1alpha ,25(OH)2D3 remains incompletely understood, and direct evidence on the participation of any of the PKC isoforms is lacking. In view of the information discussed above, we have investigated the role of Ras as well as PKCalpha in Raf 1 activation.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

Chemicals-- 1alpha ,25(OH)2D3 was kindly provided by Hoffmann-La Roche. Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum, specific Ras inhibitory peptide (VPPPVPPRRR), and protein A-Sepharose were from Sigma. Lipofectin was from Invitrogen. Sense and antisense oligodeoxynucleotides were synthesized by the DNAgency (Malvern, PA). Rabbit polyclonal anti-phosphoserine antibody was obtained from Upstate Biotechnology Inc. (Lake Placid, NY). Anti-Raf-1 monoclonal antibody and anti-(phospho)-active MAP kinase antibody (reactive against p42 and p44 isoforms) were from Promega (Madison, WI). Anti-Ras-GTPase-activating protein (GAP) antibody and donkey anti-goat IgG antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Secondary antibody goat anti-rabbit horseradish peroxidase-conjugated IgG and the Super Signal CL-HRP substrate system for enhanced chemiluminescence (ECL) were obtained from Amersham Biosciences. [gamma -32P]ATP (3,000 Ci/mmol) was from PerkinElmer Life Sciences. The compounds PD 98059, Ro 318220, calphostin C, and bisindolylmaleimide I were from Calbiochem. All other reagents were of analytical grade.

Cell Culture-- Chick skeletal muscle cells were obtained from 13-day-old chick embryo breast muscles by stirring in Earle's balanced salt solution containing 0.06% trypsin for 30 min essentially as previously described (26). The freed cells were collected by centrifugation, and the pellet was resuspended in DMEM supplemented with 10% fetal bovine serum and antibiotic-antimycotic solution. The suspension was dispersed by pipette, filtered through nylon mesh, and "preplated" on gelatin-coated Petri dishes to remove contaminating fibroblasts. The unadsorbed cells were seeded at an appropriate density (120,000 cells/cm2) in Petri dishes (100-mm diameter) and cultured at 37 °C under a humidified atmosphere (air 95%, 5% CO2). Under these conditions, myoblasts divide within the first 48 h and at day 4 become differentiated into myotubes expressing both biochemical and morphological characteristics of adult skeletal muscle fibers (27). Cells cultured for 2 days (proliferative stage) were used for treatments.

Immunoprecipitation-- After 1alpha ,25(OH)2D3 or vehicle (ethanol, < 0.01%) treatment, muscle cells were lysed (15 min at 4 °C) in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EGTA, 25 mM NaF, 0.2 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin, 2 µg/ml aprotinin, 0.25% sodium deoxycholate, and 1% Nonidet P-40 and homogenized by sonication for 15 s. Insoluble material was pelleted in a microcentrifuge at 12,000 × g for 15 min. The protein content of the clear lysates was determined according to Lowry et al. (28). Aliquots (500-700 µg of protein) were incubated overnight at 4 °C with anti-Raf-1 or anti-Ras-GAP antibodies followed by precipitation of the complexes with protein A conjugated with Sepharose. The immune complexes were washed 4 times with cold immunoprecipitation buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, 0.2 mM sodium orthovanadate, 1% Triton X-100m and 1% Nonidet P-40) and a final wash in cold phosphate-buffered saline.

Blockade with Antibodies-- Insoluble material of lysate proteins was pelleted in a microcentrifuge at 12,000 × g for 15 min. The protein content of the clear lysates was determined according to Lowry et al. (28). Aliquots (500 µg of protein) were incubated with anti-Raf-1 or anti-goat IgG antibody on an ice bath with shaking for 10 min. Then the lysates were exposed to 1 nM 1alpha ,25(OH)2D3 or vehicle (ethanol < 0.01%) for 1 min. The treatments were stopped by adding Laemmli sample buffer (29).

SDS-PAGE and Immunoblotting-- Immunoprecipitated proteins (or lysate proteins) dissolved in Laemmli sample buffer were separated on SDS-polyacrylamide (8%) gels (29) and electrotransferred to polyvinylidene difluoride membranes. The membranes were blocked for 1 h at room temperature in TBST (50 mM Tris-HCl, pH 7.4, 200 mM NaCl, 1% Tween 20) containing 5% dry milk. Membranes were subjected to immunoblotting using anti-PKCalpha , anti-phosphoserine, or anti-phosphotyrosine antibodies. Next the membranes were washed 3 times in TBST, incubated in TBST containing 1% dry milk with a 1:10,000 dilution of peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies for 1 h at room temperature, and washed 3 additional times with TBST. The membranes were then visualized using an enhanced chemiluminescent technique (ECL, Amersham Biosciences) according to the manufacturer's instructions. Images were obtained with a model GS-700 Imaging Densitomer from Bio-Rad by scanning at 600 dots per inch and printing at the same resolution. Bands were quantified using the Molecular Analyst program (Bio-Rad).

To strip the membranes for reprobing with anti-Raf-1, anti Ras-GAP, or anti-ERK1/2 antibodies, the membranes were washed for 10 min in TBST and then incubated in stripping buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, and 50 mM mercaptoethanol) for 30 min at 50 °C. The membranes were again blocked and blotted as described above.

Measurement of MAP Kinase Activity-- Muscle cells were pretreated with PD 98059 (10 µM, 10 min) or Ras inhibitor peptide (25 µM, 10 min) and then exposed for 1 min with 1 nM 1alpha ,25(OH)2D3 or vehicle (< 0.01% ethanol) at 37 °C. Lysates were prepared followed by immunoprecipitation of MAP kinase (p42 and p44) as described above. After 3 washes with immunoprecipitation buffer and 2 washes with kinase buffer (10 mM Tris-HCl, pH 7.2, 5 mM MgCl2, 1 mM MnCl2, 1 mM dithiothreitol, 0,1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 20 µg/ml leupeptin, and 20 µg/ml aprotinin), the immune complexes were incubated at 37 °C for 10 min in kinase buffer (50 µl/sample) containing myelin basic protein as an exogenous substrate for MAP kinase (20 µg/assay), 25 µM ATP, and [gamma -32P]ATP (2.5 µCi/assay). To terminate the reaction, the phosphorylated product was separated from free isotope on ion exchange phosphocellulose filters (Whatman P-81). Papers were immersed immediately into ice-cold 75 mM H3PO4, washed (1 × 5 min, 3 × 20 min), and counted in a scintillation counter.

Cell Transfection-- Transfection with oligodeoxynucleotides (ODNs) using Lipofectin was performed according to the manufacturer's instructions. ODNs were incubated with Lipofectin in DMEM for 15 min at room temperature. Plates of subconfluent cells were washed to remove serum before the addition of ODN-Lipofectin mixtures, and incubation was performed for 4 h at 37 °C. The ODN solution was removed, DMEM was added, and the plates were placed into a metabolic incubator for an additional period of 20 h. Control treatments included DMEM or Lipofectin only. Dose- and time-response studies for Lipofectin and ODNs were previously performed to establish optimum conditions for the effective blockade of PKCalpha expression (25). The following ODN sequences with phosphorothioate linkages throughout the entire ODN molecule were used: antisense-PKCalpha (AS), 5'-CATGGTYCCCCCCAACCACC-3', Y = T or C (antisense sequence against 20 nucleotides upstream of the AUG codon); sense PKCalpha (S), 5'-GGTGGTTGGGGGGRACCATG-3', R = A or G (25). Each antisense oligonucleotide was used at a final concentration of 5 µM. These antisense sequences showed no homology to any DNA in the GenBankTM except PKCalpha (human, rat, mouse, and rabbit species). Cell death in cultures under control and treatment (ODNs) conditions was measured by trypan blue staining.

Statistical Analysis-- Statistical significance of the data was evaluated using Student's t test (30), and probability values below 0.05 (p < 0.05) were considered significant. Results are expressed as the means ± S.D. from the indicated set of experiments.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

To understand how the steroid hormone 1alpha ,25(OH)2D3 controls the MAP kinase cascade in skeletal muscle cells, it is essential to identify the molecules that participate in the cellular sequence of events involved in the signaling pathway of this steroid hormone. As in other cell types, Raf-1 and MEK belong to the MAP kinase cascade that leads to muscle cell proliferation (31, 32). As a major step in this direction, we report here for the first time that 1alpha ,25(OH)2D3 stimulation of the MAPK (ERK1/2) pathway in skeletal muscle cells involves at least in part rapid activation of Raf-1 and provide information on the mechanism of action by which this hormone-regulated event takes place.

The complex process of Raf activation is still incompletely understood. Existing data suggest that activation of Raf-1 engages multiple factors and steps (9, 10), and phosphorylation of Raf-1 on Ser 338 and Tyr-341 is a critical step in this process (11). To evaluate whether the serine-threonine kinase Raf-1 is part of the 1alpha ,25(OH)2D3-signaling mechanism in chick muscle cells, we first investigated the effect of the steroid hormone on Raf-1 serine phosphorylation. To that end, muscle cells were exposed to 1 nM 1,25(OH)2D3 (0.5-5 min), and cell lysates were immunoprecipitated with a highly specific anti-Raf-1 monoclonal antibody followed by immunoblotting with anti-phosphoserine antibody. As shown in Fig. 1, 1alpha ,25(OH)2D3 caused a time-dependent increase in Raf-1 phosphorylation in muscle cells. The stimulation of Raf-1 serine phosphorylation could be detected already at 30 s, increased 1-fold over basal at 60 s, and reached a maximum after 2 min of hormone exposure (3-fold).


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 1.   Time course of 1alpha ,25(OH)2D3 stimulation of Raf-1 serine phosphorylation. Chick skeletal muscle cells were incubated in the presence of 1alpha ,25(OH)2D3 (1 nM) or vehicle (ethanol <0.01%) for the indicated times. Immunoprecipitation of Raf-1 and immunoblotting with an anti-phosphoserine (anti-P-serine) antibody were carried out in cell lysates as detailed under "Materials and Methods." A, representative immunoblot. B, quantification by scanning volumetric densitometry of blots from three independent experiments performed in duplicate; averages ± S.D. are given. *, p < 0.01, with respect to the control.

It has been reported that the small G protein Ras is the direct upstream activator of Raf, which in its GTP-bound activated form binds to the Ras binding domain (Raf-RBD) and recruits the inactive cytoplasmic Raf to the plasma membrane for activation (33). This binding induces a conformational change of Raf-1 that yields an opened structure suitable for phosphorylation by membrane-associated kinases. To study Ras-dependent changes in Raf activation induced by 1alpha ,25(OH)2D3, muscle cells were preincubated for 2 h with a specific Ras inhibitor peptide, which blocks the association of Grb2 and Sos1 and, thus, the nucleotide exchange of Ras, avoiding its activation (34), followed by hormone treatment (1 nM, 2 min). As shown in Fig. 2, Ras inhibition abolished Raf-1 serine phosphorylation by 1alpha ,25(OH)2D3, demonstrating that Ras is necessary for 1alpha ,25(OH)2D3-Raf-1 activation in these cells. At the concentration used (25 µM), it is likely that sufficient amounts of the inhibitor peptide entered the cells by endocytosis to reach the Kd (25 nM) for its binding to Grb2 (35).


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 2.   1alpha ,25(OH)2D3-induced serine phosphorylation (P) of Raf-1 is suppressed by Ras inhibitor peptide. Chick skeletal muscle cells were preincubated for 2 h with a specific Ras inhibitor peptide (25 µM) and then exposed to 1 nM 1alpha ,25(OH)2D3 for 2 min. After cell lysis, comparable aliquots were immunoprecipitated with an anti-Raf-1 antibody followed by Western blotting with anti-phosphoserine antibody as described under "Materials and Methods." A, representative immunoblot. B, quantification by scanning volumetric densitometry of blots of three independent experiments performed in duplicate; averages ± S.D. are given. *, p < 0.01, with respect to basal; **, p < 0.05 with respect to 1alpha ,25(OH)2D3 stimulation.

Ras proteins play a central role in control of cell proliferation, differentiation, and other cellular functions (36). They function by cycling between inactive GDP- and active GTP-bound forms. This molecular switch is mainly regulated by guanine nucleotide exchange factors, which catalyze an exchange of GTP for GDP, and by GAPs, which activate the intrinsic GTPase activity of Ras and, thus, convert Ras-GTP to Ras-GDP (37). It has been reported that tyrosine phosphorylation of Ras-GAPs on Tyr-460 allows rise of its GTPase activity (38), promoting Ras inactivation. Therefore, the tyrosine phosphorylation of Ras-GAP would promote Ras inactivation by Ras-GAP-induced hydrolysis of Ras-GTP bound. We next explored the effect of 1alpha ,25(OH)2D3 on Ras-GAP tyrosine phosphorylation. As shown in Fig. 3, muscle cells treated with 1 nM 1alpha ,25(OH)2D3 showed a rapid and transient tyrosine de-phosphorylation of Ras-GAP, which was maximal at 0.5 min (-80%) and returned to basal level upon 10 min of hormone exposure. This result suggests that inhibition of Ras-GTP hydrolysis is part of the mechanism by which 1alpha ,25(OH)2D3 activates Ras in skeletal muscle cells.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 3.   Transient inactivation of Ras-GAP by tyrosine dephosphorylation (P) in response to 1alpha ,25(OH)2D3. Lysates from chick muscle cells exposed to 1 nM 1alpha ,25(OH)2D3 for the indicated times were immunoprecipitated with anti-Ras-GAP antibody followed by immunoblot analysis with anti-phosphotyrosine antibody as described under "Materials and Methods." A representative immunoblot from three independent experiments is shown. The blotted membranes were re-probed with anti-Ras-GAP antibody to evaluate the equivalence of Ras-GAP content among the different experimental conditions (bottom panel).

PKC, discovered as a serine/threonine kinase (39), mediates intracellular responses to a variety of agonists including 1alpha ,25(OH)2D3 (40). The direct phosphorylation of Raf-1 by PKC isoforms has been suggested as an activation mechanism of PKC on the Raf-1/ERK1/2-signaling pathway (16, 18). In previous investigations we have demonstrated that stimulation of the extracellular signal-regulated mitogen-activated protein kinases ERK1 and ERK2 by 1alpha ,25(OH)2D3 is mediated by PKC and Ca2+ (23). These data prompted us to study whether PKC participates in Raf-1 serine phosphorylation induced by the hormone. To that end, muscle cells were pretreated with the PKC inhibitors calphostin C or bisindolylmaleimide I and stimulated with 1alpha ,25(OH)2D3 (1 nM, 2 min) followed by immunoprecipitation of cell lysates with anti-Raf-1 antibody and then immunoblotting with anti-phosphoserine antibody. As shown in Fig. 4, Raf-1 serine phosphorylation was suppressed by either PKC inhibitor. Moreover, Ro 318220, a PKC specific inhibitor that blocks all PKC isoforms completely, abolished Raf-1 serine phosphorylation (Fig. 5) and further confirmed that hormone activation of Raf-1 is a PKC-dependent event. It has been shown that PKCalpha can directly phosphorylate and activate Raf-1 in other cell types (18). PKCalpha belongs to the family of conventional protein kinases that are Ca2+-dependent. It is well recognized that when skeletal muscle cells are subjected to 1alpha ,25(OH)2D3 stimulation, a rapid increase of intracellular Ca2+ (22), inositol trisphosphate, and diacylglycerol (43) and activation of PKCalpha (44) occurs. To demonstrate that PKCalpha is involved in Raf-1 activation, we used antisense technology to block PKCalpha protein expression. Cultured muscle cells were transfected with an antisense oligodeoxynucleotide against 20 nucleotides upstream of the AUG codon of PKCalpha mRNA to suppress expression of its encoded protein. Under these conditions, phosphorylation of Raf-1 induced by 1alpha ,25(OH)2D3 was fully abolished (Fig. 6A, upper panel). Suppression of PKCalpha expression was verified by immunoblotting of cell lysates with anti-PKCalpha antibody (Fig. 6A, bottom panel). Although we cannot rule out the possibility that other PKC isoforms may also contribute to Raf-1 serine phosphorylation, our results clearly show that PKCalpha is also a component of the mitogenic pathway leading to Raf-1 activation in response to 1alpha ,25(OH)2D3 stimulation.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 4.   PKC inhibitors calphostin C and bisindolylmaleimide I suppress muscle cell Raf-1 serine phosphorylation (P) induced by 1alpha ,25(OH)2D3. Muscle cells were treated with 1 nM 1alpha ,25(OH)2D3 for 2 min in the absence or presence of calphostin C (100 nM) or bisindolylmaleimide I (30 nM). The cells were then lysed and immunoprecipitated with anti-Raf-1 antibody followed by Western blotting with anti-phosphoserine antibody as described under "Materials and Methods." A, representative immunoblot. B, quantification by scanning volumetric densitometry of blots from three independent experiments performed in duplicate; averages ± S.D. are given. *, p < 0.01 with respect to basal and 1alpha ,25(OH)2D3 stimulation in the presence of PKC inhibitors.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 5.   The PKC inhibitor Ro 318220 blocks the activation of Raf-1 induced by 1,25(OH)2D3. Muscle cells were treated with 1 nM 1,25(OH)2D3 for 2 min in the absence or presence of Ro 318220 (200 nM). Then cells were lysed and immunoprecipitated with anti Raf-1 antibody followed by Western blotting with anti-phosphoserine (anti-P-serine) antibody as described under "Materials and Methods." A, representative immunoblot. B, quantification by scanning volumetric densitometry of blots from three independent experiments performed in duplicate; averages ± S.D. are given. *, p < 0.01, with respect to basal; **, p < 0.05 with respect to 1alpha ,25(OH)2D3 stimulation.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 6.   Effects of an antisense oligodeoxynucleotide against PKCalpha mRNA on 1,alpha 25(OH)2D3-induced Raf-1 serine phosphorylation. Muscle cells were transfected with a sense (ODN-S) or an antisense (ODN-AS) oligodeoxynucleotide against PKCalpha mRNA or Lipofectin (LPF) to have a basal expression control. 48 h later the cells were exposed to 1 nM 1alpha ,25(OH)2D3 for 2 min. Raf-1 was immunoprecipitated from cell lysates and then immunoblotted with anti-phosphoserine (anti-P-serine) antibody. A, top panel, representative blot showing changes in Raf-1 serine phosphorylation; bottom panel, representative blot showing the amount of PKCalpha expressed in the cells. B, quantification by scanning volumetric densitometry of top blot from four independent experiments performed in duplicate; averages ± S.D. are given. p < 0.01 (*) and p < 0.05 (**), with respect to the corresponding control.

We finally evaluated the effects of Ras, Raf-1, and MEK inhibition on MAP kinase activity and tyrosine phosphorylation changes induced by 1alpha ,25(OH)2D3. To measure MAPK activity, the enzyme from cell lysates exposed for 1 min to the hormone (1 nM) was immunoprecipitated with an anti-(phospho)-active MAPK antibody, which recognizes both the p42 and p44 active isoforms, and then incubated with [gamma -32P]ATP and myelin basic protein, as exogenous MAPK substrate. As previously shown (22), 1alpha ,25(OH)2D3 caused a 3-fold increase in MAP kinase activity (Fig. 7). The hormone effect was abolished by either the Ras inhibitor peptide or compound PD 98059, which prevents the activation of the dual MAPK kinase MEK by Raf-1 (45). These results are in agreement with previous observations showing that PD 98059 prevents the stimulation of skeletal muscle cell proliferation by 1alpha ,25(OH)2D3 (22). When muscle cell lysates were preincubated with anti-Raf-1 antibody and then exposed to 1alpha ,25(OH)2D3 (1 nM, 1 min), hormone-induced MAPK tyrosine phosphorylation was also abolished (Fig. 8). Furthermore, suppression of PKCalpha expression in cells transfected with the antisense oligodeoxynucleotide against PKCalpha mRNA abolished by 70% the phosphorylation of MAPK induced by 1alpha ,25(OH)2D3 (Fig. 9). These results stress the relevance of PKCalpha , Ras, Raf-1, and MEK in the 1alpha ,25(OH)2D3-signaling pathway, which results in MAP kinase stimulation in muscle cells.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 7.   Stimulation of MAP kinase activity by 1alpha ,25(OH)2D3 is mediated by Ras and MEK. Cells were incubated for 1 min with 1alpha ,25(OH)2D3 (1 nM) in the absence or presence of a MEK-specific inhibitor (PD 98059, 10 µM) or a Ras inhibitory peptide (25 µM). Immunoprecipitation of MAP kinase and assay of its activity using [gamma -32P]ATP and myelin basic protein as exogenous substrate were carried out in cell lysates as described under "Materials and Methods." Results are the average of three independent experiments performed in triplicate ± S.D. *, p < 0.01, with respect to basal and 1alpha ,25(OH)2D3 stimulation in the presence of inhibitors.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 8.   1alpha ,25(OH)2D3 stimulation of MAP kinase tyrosine phosphorylation (P) is suppressed by antibody inhibition of Raf-1. After cell lysis, comparable aliquots of lysate protein (500 µg) were incubated with anti-Raf antibody (2 µg) or anti-goat IgG antibody (2 µg, as a control of the basal levels of MAP kinase) on an ice bath for 10 min. Then the lysates were exposed to 1alpha ,25(OH)2D3 (1 nM) or vehicle ethanol (<0.01%) for 1 min. Proteins were resolved by SDS-PAGE followed by immunoblotting with anti-(phospho)-active MAP kinase as described under "Materials and Methods." A, representative immunoblot. B, quantification by scanning volumetric densitometry of blots from three independent experiments performed in duplicate; averages ± S.D. are given. *, p < 0.01 with respect to basal and 1alpha ,25(OH)2D3 stimulation in the presence of anti-Raf antibody.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 9.   Effects of an antisense oligodeoxynucleotide against PKCalpha mRNA on 1alpha ,25(OH)2D3-induced MAPK phosphorylation. Muscle cells were transfected (T) with a sense (ODN-S) or an antisense (ODN-AS) oligodeoxynucleotide against PKCalpha mRNA. 48 h later the cells were exposed to 1 nM 1alpha ,25(OH)2D3 for 2 min and then lysed. Proteins were resolved by SDS-PAGE followed by immunoblotting with anti-(phospho)-active MAP kinase as described under "Materials and Methods." Top panel, representative blot showing changes in phospho-MAPK. Bottom panel, quantification by scanning volumetric densitometry of the top blot from three independent experiments performed in duplicate; averages ± S.D. are given. p < 0.01 (*) and p < 0.05 (**), with respect to the corresponding control.

With regard to the initiation of the 1alpha ,25(OH)2D3 signal that leads to activation of the MAP kinase pathway, new lines of evidence indicate that steroid hormone intracellular receptors mediate rapid, non-transcriptional stimulation of MAPK via interaction with upstream components of the cascade (46). More specifically, we recently reported that activation of MAPK by 1alpha ,25(OH)2D3 in muscle cells is preceded by rapid tyrosine phosphorylation of the vitamin D receptor followed by its association with Src (47). Subsequent interaction with the Shc-Grb2-Sos-Ras complex may then occur as observed in keratinocytes (48). However, the involvement of a novel 1alpha ,25(OH)2D3 membrane receptor, whose existence in various hormone target cell types has received experimental support (41, 42, 49), cannot be excluded. In summary, our results demonstrate for the first time in a 1alpha ,25(OH)2D3 target cell that activation of Raf-1 via Ras (through inhibition of Ras-GAP activity by tyrosine dephosphorylation) and PKCalpha -dependent serine phosphorylation play a central role in hormone stimulation of the MAPK-signaling pathway (depicted in the schematic diagram of Fig. 10).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 10.   Schematic diagram indicating the chain of events leading to 1alpha ,25(OH)2D3 activation of MAP kinase in skeletal muscle cells. By acting at the plasma membrane, 1alpha ,25(OH)2D3 inhibits Ras-GAP activity by tyrosine dephosphorylation (YP), which elicits Ras activation. The hormone also stimulates PKCalpha . Activated Ras along with PKCalpha lead to serine phosphorylation and stimulation of Raf-1 followed by MEK and MAP kinase activation.


    FOOTNOTES

* This research was supported by grants from the Agencia Nacional de Promoción Cientifica y Tecnológica, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), and Universidad Nacional del Sur, Argentina.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Depto. Biología, Bioquímica y Farmacia, Universidad Nacional del Sur, San Juan 670, 8000 Bahía Blanca, Argentina. Tel.: 54-291-4595101 (ext. 2430); Fax: 54-291-4595130; E-mail: rboland@criba.edu.ar.

Published, JBC Papers in Press, November 1, 2002, DOI 10.1074/jbc.M205732200

    ABBREVIATIONS

The abbreviations used are: MEK, mitogen-activated protein (MAP) kinase (MAPK) kinase; ERK, extracellular signal-regulated kinase; PKC, protein kinase C; 1alpha , 25(OH)2D3, 1alpha ,25-dihydroxyvitamin D3; DMEM, Dulbecco's modified Eagle's medium; GAP, GTPase-activating protein; ODN, oligodeoxynucleotide.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

1. Daum, G., Eisenmann-Tape, I., Fries, H-W., Troppmair, J., and Rapp, U. R. (1994) Trends Biochem. Sci. 19, 474-480[CrossRef][Medline] [Order article via Infotrieve]
2. Troppmair, J., Bruder, J. T., App, H., Cai, H., Liptak, L., Szeberenyi, J., M., Cooper, G., and Rapp, U. R. (1992) Oncogene 7, 1867-1873[Medline] [Order article via Infotrieve]
3. Wood, K. W., Sarnecki, C., Roberts, T. M., and Blenis, J. (1992) Cell 68, 1041-1051[Medline] [Order article via Infotrieve]
4. Kyriakis, J. M., App, H., Zhang, X., Banerjee, P., Brautigan, D. L., Rapp, U. R., and Avruch, J. (1992) Nature 358, 417-421[CrossRef][Medline] [Order article via Infotrieve]
5. Howe, l. R., Leevers, S. J., Gomez, N., Nakielny, S., Cohen, P., and Marsahall, C. J. (1992) Cell 71, 335-342[Medline] [Order article via Infotrieve]
6. Chen, R. H., Sarnecki, C., and Blenis, J. (1992) Mol. Cell. Biol. 12, 915-927[Abstract]
7. Hill, C. S., Marais, R., John, S., Wynne, J., Dalton, S., and Treisman, R. (1993) Cell 73, 395-406[Medline] [Order article via Infotrieve]
8. Moodie, S. A., Willumsen, B. M., Weber, M. J., and Wolfman, A. (1993) Science 260, 1658-1661[Medline] [Order article via Infotrieve]
9. Stokoe, D., Macdonald, S. G., Cadwallader, K., Symons, M., and Hancock, J. F. (1994) Science 264, 1463-1467[Medline] [Order article via Infotrieve]
10. Leevers, S. J., Paterson, H. F., and Marshall, C. J. (1994) Nature 369, 411-414[CrossRef][Medline] [Order article via Infotrieve]
11. Dent, P., Jelinek, T., Morrison, D. K., Weber, M. J., and Sturgill, T. W. (1995) Science 268, 1902-1906[Medline] [Order article via Infotrieve]
12. Fabian, J. R., Darr, I. O., and Morrison, D. K. (1993) Mol. Cell. Biol. 13, 7170-7179[Abstract]
13. Marais, R., Light, Y., Paterson, H. F., and Marshall, C. J. (1995) EMBO J. 14, 3136-3145[Abstract]
14. Qiu, Z. H., and Leslie, C. C. (1994) J. Biol. Chem. 269, 19480-19487[Abstract/Free Full Text]
15. Johannes, F. J., Prestle, J., Eis, S., Oberhagemann, P., and Pfizenmaier, K. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 8572-8576[Abstract]
16. Schonwasser, D. C., Marais, R. M., Marshall, C. J., and Parker, P. J. (1998) Mol. Cell. Biol. 18, 790-798[Abstract/Free Full Text]
17. Marais, R., Light, Y., Mason, C., Paterson, H., Olson, M. F., and Marshall, C. J. (1998) Science 280, 109-112[Abstract/Free Full Text]
18. Kolch, W., Heidecker, G., Kochs, G., Humme, l R., Vahidi, H., Mischak, H., Finkenzeller, G., Marme, D., and Rapp, U. R. (1993) Nature 364, 249- 252[CrossRef][Medline] [Order article via Infotrieve]
19. Boland, R., de Boland, A. R., Marinissen, M. J., Santillán, G., Vazquez, G., and Zanello, S. (1995) Mol. Cell. Endocrinol. 114, 1-8[CrossRef][Medline] [Order article via Infotrieve]
20. de Boland, A. R., and Boland, R. (1987) Endocrinology 120, 1858-1864[Abstract]
21. de Boland, A. R., and Boland, R. (1994) Cell. Signal. 6, 717-724[CrossRef][Medline] [Order article via Infotrieve]
22. Morelli, S., Buitrago, C., Vazquez, G., de Boland, A. R., and Boland, R. (2000) J. Biol. Chem. 275, 36021-36028[Abstract/Free Full Text]
23. Morelli, S., Buitrago, C., Boland, R., and de Boland, A. R. (2001) Mol. Cell. Endocrinol. 173, 41-52[CrossRef][Medline] [Order article via Infotrieve]
24. Capiati, D., Tellez Iñón, M. T., and Boland, R. L. (1999) Mol. Cell. Endocrinol. 153, 39-45[CrossRef][Medline] [Order article via Infotrieve]
25. Capiati, D. A., Vazquez, G., Tellez-Iñón, M. T., and Boland, R. L. (2001) Cell Prolif. 33, 307-315[CrossRef]
26. Vazquez, G., and de Boland, A. R. (1993) Biochem. Mol. Biol. Int. 31, 677-684[Medline] [Order article via Infotrieve]
27. Capiati, D. A., Limbozzi, F., Téllez Iñón, M. T., and Boland, R. (1999) J. Cell. Biochem. 74, 292-300[CrossRef][Medline] [Order article via Infotrieve]
28. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) J. Biol. Chem. 195, 265-277
29. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
30. Snedecor, G., and Cochran, W. (1967) Statistical Methods , pp. 59-62, Iowa State University Press, Ames, Iowa
31. Pizon, V., and Baldacci, G. (2000) Oncogene 19, 6074-6081[CrossRef][Medline] [Order article via Infotrieve]
32. Lin, C. C., Shyr, M. H., Chien, C. S., Wang, C. C., Chiu, C. T., Hsiao, L. D., and Yang, C. M. (2001) Cell. Signal. 13, 257-267[CrossRef][Medline] [Order article via Infotrieve]
33. Slupsky, J. R., Weber, C. K., Ludwing, S., and Rapp, U. R. (1998) in Cell Growth and Oncogenesis (Bannasch, P. , Kondac, D. , Papa, S. , and Tager, J. M., eds) , Birkhaeuser Verlag, Basel, Switzerland
34. Li, N., Batzer, A., Daly, R., Yajnik, V., Skolnik, E., Chardin, P., Bar-Sagi, D., Margolis, B., and Schlessinger, J. (1993) Nature 363, 85-88[CrossRef][Medline] [Order article via Infotrieve]
35. Lemmon, M. A., Ladbury, J. E., Mandiyan, V., Zhou, M., and Schlessinger, J. (1994) J. Biol. Chem. 269, 31653-31658[Abstract/Free Full Text]
36. Bar-Sagi, D., and Hall, A. (2000) Cell 103, 227-238[Medline] [Order article via Infotrieve]
37. Sasa, H., Nakata, H., Umekage, T., Namina, M., Tomiyama, K., Arimura, S., Kobayashi, M., and Watanabe, Y. (1998) J. Pharmacol. 76, 121-124
38. Borowski, P., Kornetzky, L., Heiland, M., Roloff, S., Weber, W., and Laufs, R. (1996) Biochem. Mol. Biol. Int. 39, 635-646[Medline] [Order article via Infotrieve]
39. Parker, P. J., Coussens, L., Totty, N., Rhee, L., Young, S., Chen, E., Stabel, S., Waterfield, M. D., and Ullrich, A. (1986) Science 233, 853-859[Medline] [Order article via Infotrieve]
40. Walters, M. R. (1992) Endocrinol. Rev. 13, 719-764[Medline] [Order article via Infotrieve]
41. Baran, D. T., Quail, J. M., Ray, R., Leszyk, J., and Honeyman, T. (2000) J. Cell. Biochem. 78, 34-46[CrossRef][Medline] [Order article via Infotrieve]
42. Nemere, I., Schwartz, Z., Pedrozo, H., Sylvia, V. L., Dean, D. D., and Boyan, B. D. (1998) J. Bone Miner. Res. 13, 1353-1359[Medline] [Order article via Infotrieve]
43. Morelli, S., de Boland, A. R., and Boland, R. (1993) Biochem. J. 289, 675-679[Medline] [Order article via Infotrieve]
44. Capiati, D., Vazquez, G., Tellez-Iñón, M. T., and Boland, R. (2000) J. Cell. Biochem. 77, 200-212[Medline] [Order article via Infotrieve]
45. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., and Saltiel, A. R. (1995) J. Biol. Chem. 270, 27489-27494[Abstract/Free Full Text]
46. Migliaccio, A., Piccolo, D., Castoria, G., Di, Domenico, M., Bilancio, A., Lombardi, M., Gong, W., Beato, M., and Auricchio, F. (1998) EMBO J. 17, 2008-2018[Free Full Text]
47. Buitrago, C., Vazquez, G., de Boland, A. R., and Boland, R. (2000) J. Cell. Biochem. 79, 274-281[CrossRef][Medline] [Order article via Infotrieve]
48. Gniadecki, R. (1996) J. Invest. Dermatol. 106, 1212-1217[Abstract]
49. Nemere, I., Dormanen, M. C., Hammond, M. W., Okamura, W. H., and Norman, A. W. (1994) J. Biol. Chem. 269, 23750-23756[Abstract/Free Full Text]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.